<DOC>
	<DOCNO>NCT01728857</DOCNO>
	<brief_summary>Evaluate effect tissue optimization cryolipolysis procedures outcome non-invasive fat reduction use ZELTIQ System .</brief_summary>
	<brief_title>Tissue Optimization Cryolipolysis Procedures Fat Layer Reduction</brief_title>
	<detailed_description />
	<mesh_term>Lipid Metabolism Disorders</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female subject &gt; 18 year age &lt; 65 year age . 2 . Subject clearly visible fat intend treatment area , investigator 's opinion , may benefit treatment ( ) . 3 . Subject weight change exceed 10 pound precede month . 4 . Subject body mass index ( BMI ) less 30 . BMI define weight pound multiply 703 divide square height inch . 5 . Subject agree maintain his/her weight ( i.e. , within 5 pound ) make major change diet lifestyle course study . 6 . Subject read sign write informed consent form . Exclusion Criteria 1 . Subject present significant asymmetry intend treatment area . 2 . Subject surgical procedure ( ) area intend treatment past 5 years.. 3 . Subject invasive fat reduction procedure ( e.g. , liposuction , abdominoplasty , mesotherapy ) area intend treatment past 5 year . 4 . Subject noninvasive fat reduction and/or body contour procedure area intend treatment within past 6 month . 5 . Subject need administer , know history subcutaneous injection area intend treatment ( e.g. , heparin , insulin ) within past month . 6 . Subject known history cryoglobulinemia , cold urticaria , paroxysmal cold hemoglobinuria . 7 . Subject known history Raynaud 's disease , know condition response cold exposure limit blood flow skin . 8 . Subject history bleed disorder take medication investigator 's opinion may increase subject 's risk bruising . 9 . Subject take take diet pill weight control supplement within past month . 10 . Subject dermatological condition , moderate excessive skin laxity , scar location treatment site may interfere treatment evaluation ( stretch mark exclusion ) . 11 . Subject active implant device pacemaker , defibrillator , drug delivery system . 12 . Subject pregnant intending become pregnant next 5 month . 13 . Subject lactate lactate past 6 month . 14 . Subject history hernia area treat . 15 . Subject unable unwilling comply study requirement . 16 . Subject currently enrol clinical study unapproved investigational drug device . 17 . Any condition laboratory value would , professional opinion investigator , potentially affect subject 's response integrity data would pose unacceptable risk subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Lipolysis</keyword>
	<keyword>Cryolipolysis</keyword>
	<keyword>Fat Reduction</keyword>
</DOC>